Australia appears to be gain access to potentially transformative medication for excess weight: Retatrutide. This dual agonist – working on both GLP-1 and GIP receptors – demonstrates promising efficacy in global studies, indicating meaningful reductions in body fat. While availability is pending with TGA, many Australians battling obesity are